Approval Package for:

APPLICATION NUMBER:

205551Orig1s000

Trade Name: TRIUMEQ fixed-dose combination tablets, 600/50/300 mg.

Generic Name: Abacavir sulfate, dolutegravir, and lamivudine

Sponsor: ViiV Healthcare Company

Approval Date: August 22, 2014

Indication: Provides for the use of TRIUMEQ (abacavir sulfate, dolutegravir, and lamivudine), fixed-dose combination tablets, 600/50/300 mg for the treatment of HIV-1 infection
## CONTENTS

Reviews / Information Included in this NDA Review.

<table>
<thead>
<tr>
<th>Category</th>
<th>Included</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approval Letter</td>
<td>X</td>
</tr>
<tr>
<td>Other Action Letters</td>
<td></td>
</tr>
<tr>
<td>Labeling</td>
<td>X</td>
</tr>
<tr>
<td>REMS</td>
<td></td>
</tr>
<tr>
<td>Summary Review</td>
<td></td>
</tr>
<tr>
<td>Officer/Employee List</td>
<td>X</td>
</tr>
<tr>
<td>Office Director Memo</td>
<td></td>
</tr>
<tr>
<td>Cross Discipline Team Leader Review</td>
<td></td>
</tr>
<tr>
<td>Medical Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Chemistry Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Environmental Assessment</td>
<td></td>
</tr>
<tr>
<td>Pharmacology Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Statistical Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Microbiology / Virology Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Clinical Pharmacology/Biopharmaceutics Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Other Reviews</td>
<td>X</td>
</tr>
<tr>
<td>Risk Assessment and Risk Mitigation Review(s)</td>
<td></td>
</tr>
<tr>
<td>Proprietary Name Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Administrative/Correspondence Document(s)</td>
<td>X</td>
</tr>
</tbody>
</table>
APPLICATION NUMBER:

205551Orig1s000

APPROVAL LETTER
Dear Ms. Auld:

Please refer to your New Drug Application (NDA) dated received October 22, 2013, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act, for TRIUMEQ (abacavir sulfate, dolutegravir, and lamivudine), fixed-dose combination tablets, 600/50/300 mg.

We acknowledge receipt of your amendments dated:

<table>
<thead>
<tr>
<th>Date 1</th>
<th>Date 2</th>
<th>Date 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>October 23, 2013</td>
<td>February 26, 2014</td>
<td>June 2, 2014</td>
</tr>
<tr>
<td>October 23, 2013</td>
<td>March 12, 2014</td>
<td>June 12, 2014</td>
</tr>
<tr>
<td>December 17, 2013</td>
<td>March 14, 2014 (x2)</td>
<td>June 30, 2014</td>
</tr>
<tr>
<td>January 31, 2014</td>
<td>April 18, 2014</td>
<td>August 20, 2014</td>
</tr>
<tr>
<td>February 18, 2014</td>
<td>May 15, 2014</td>
<td></td>
</tr>
<tr>
<td>February 19, 2014</td>
<td>May 19, 2014</td>
<td></td>
</tr>
</tbody>
</table>

This new drug application provides for the use of TRIUMEQ (abacavir sulfate, dolutegravir, and lamivudine), fixed-dose combination tablets, 600/50/300 mg for the treatment of HIV-1 infection.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

**WAIVER OF HIGHLIGHTS SECTION**

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.
CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for Medication Guide, and text for Warning Card). Information on submitting SPL files using eLIST may be found in the guidance for industry SPL Standard for Content of Labeling Technical Qs and As, available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible via publicly available labeling repositories.

CARTON AND IMMEDIATE CONTAINER LABELS

Submit final printed carton and immediate container labels that are identical to the enclosed carton and immediate container labels as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008). Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “Final Printed Carton and Container Labels for approved NDA 205551.” Approval of this submission by FDA is not required before the labeling is used.

Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

ADVISORY COMMITTEE

Your application for TRIMUEQ (abacavir sulfate, dolutegravir, and lamivudine) was not referred to an FDA advisory committee because this drug is not the first in its class, the application did not raise significant safety or efficacy issues that were unexpected for a drug of this class, and because outside expertise was not necessary as there were no significant issues identified that would benefit from advisory committee discussion.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.
We are waiving the pediatric study requirement for ages 0 to less than 2 years because necessary studies are impossible or highly impracticable. This is because the number of these patients is too small.

We are deferring submission of your pediatric studies for ages 2 to less than 18 years for this application because this product is ready for approval for use in adults and the pediatric studies have not been completed.

Your deferred pediatric studies required under section 505B(a) of the FDCA are required postmarketing studies. The status of these postmarketing studies must be reported annually according to 21 CFR 314.81 and section 505B(a)(3)(B) of the FDCA. These required studies are listed below.

2768-1 Conduct a pediatric trial to evaluate the pharmacokinetics, safety and antiviral activity (efficacy) of abacavir/dolutegravir/lamivudine FDC tablets in HIV infected pediatric subjects 2 years to less than 6 years of age. The safety and antiviral activity (efficacy) of abacavir/dolutegravir/lamivudine FDC tablets in pediatric subjects should be evaluated for a minimum of 24 weeks.

Final Protocol Submission: 12/31/2017
Trial Completion: 01/31/2022
Final Report Submission: 01/31/2023

2768-2 Conduct a pediatric trial to evaluate the pharmacokinetics, safety and antiviral activity (efficacy) of abacavir/dolutegravir/lamivudine FDC tablets in HIV infected pediatric subjects 6 years to less than 12 years of age and in children older than 12 years of age who weigh less than 40 kg. The safety and antiviral activity (efficacy) of abacavir/dolutegravir/lamivudine FDC tablets in pediatric subjects should be evaluated for a minimum of 24 weeks.

Final Protocol Submission: 12/31/2017
Trial Completion: 01/31/2022
Final Report Submission: 01/31/2023

2768-3 Evaluate the pharmacokinetics, safety and antiviral activity (efficacy) of abacavir/dolutegravir/lamivudine FDC tablets in HIV infected pediatric subjects 12 years to less than 18 years of age and weighing at least 40 kg. The safety and antiviral activity (efficacy) of abacavir/dolutegravir/lamivudine FDC tablets in pediatric subjects should be evaluated for a minimum of 24 weeks. A clinical trial in children 12 to less than 18 years of age and weighing at least 40 kg may not be required if dosing recommendation for the FDC tablets can be supported by pediatric trials already conducted with the individual drug products.

Final Protocol Submission: 12/31/2017
Trial Completion: 01/31/2022
Final Report Submission: 01/31/2023
Submit the protocols to your IND 114,820, with a cross-reference letter to this NDA.

Reports of these required pediatric postmarketing studies must be submitted as a new drug application (NDA) or as a supplement to your approved NDA with the proposed labeling changes you believe are warranted based on the data derived from these studies. When submitting the reports, please clearly mark your submission "SUBMISSION OF REQUIRED PEDIATRIC ASSESSMENTS" in large font, bolded type at the beginning of the cover letter of the submission.

**PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Prescription Drug Promotion  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf. Information and Instructions for completing the form can be found at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).
If you have any questions, call Sohail Mosaddegh, PharmD, Regulatory Project Manager, at (301) 796-4876 or (301) 796-1500.

Sincerely yours,

{See appended electronic signature page}

Debra Birnkrant, MD
Director
Division of Antiviral Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

Enclosures:
Content of Labeling
Carton and Container Labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

DEBRA B BIRNKRANT
08/22/2014